ReviewMetabolites2026
Metabolite-Related Evidence Linking Metabolic Measures to Patient-Reported Outcomes in Inflammatory Bowel Disease: A Critical Narrative Review.
Review in Metabolites, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesPatient-reported outcomes (PROs) capture important dimensions of inflammatory bowel disease (IBD), including fatigue, questionnaire-defined mood-related symptom burden, pain, sleep disturbance, bowel urgency and impaired health-related quality of life, yet these outcomes are incompletely explained by conventional inflammatory markers. Metabolite-related measures may capture host-microbe co-metabolism relevant to patient-reported burden.
methodsThis critical narrative review synthesized adult IBD literature linking metabolite-related measures with patient-reported symptom domains. PubMed/MEDLINE, Embase.com, Scopus and Web of Science Core Collection were searched through 11 June 2026; purposive source selection supported critical narrative synthesis rather than exhaustive enumeration.
resultsOur structured search identified only a small number of human studies, mainly in fatigue and questionnaire-defined mood-related symptom burden. Studies included serum, plasma or fecal metabolite measurements, exploratory multi-omics, inferred microbial metabolic functions and interventional pathway testing. Fatigue was associated with serum amino-acid-related changes, plasma lipidomic alterations and fecal untargeted metabolomic and microbiome differences; inferred microbial functional modules were also reported. Mood-related burden was associated with serum and fecal metabolomic changes, bile-acid profiles and microbiota-derived functional signals. Within our search and eligibility criteria, no human studies paired measured metabolites with sleep-, pain- or urgency-specific patient-reported outcome measures (PROMs); evidence for multidimensional clusters was insufficient.
conclusionsWe did not identify a metabolite-related signature for the assessment of patient-reported burden that had undergone both analytical and clinical validation; findings support candidate associations and exploratory signatures. Future work requires longitudinal, phenotype-stratified cohorts, validated PROMs, rigorous metabolomics methodology, causal modeling, inflammatory and dietary metadata, multiple-testing control and independent validation for clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.